Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to 0.43.

  • Astrazeneca's Equity Ratio rose 871.16% to 0.43 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.43, marking a year-over-year increase of 871.16%. This contributed to the annual value of 0.43 for FY2025, which is 871.16% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Equity Ratio is 0.43, which was up 871.16% from 0.4 recorded in Q3 2025.
  • Astrazeneca's 5-year Equity Ratio high stood at 377.76 for Q4 2021, and its period low was 0.21 during Q2 2021.
  • Its 5-year average for Equity Ratio is 19.24, with a median of 0.39 in 2022.
  • Its Equity Ratio has fluctuated over the past 5 years, first surged by 16109402.34% in 2021, then crashed by 9989.83% in 2022.
  • Over the past 5 years, Astrazeneca's Equity Ratio (Quarter) stood at 377.76 in 2021, then tumbled by 99.9% to 0.38 in 2022, then rose by 0.84% to 0.39 in 2023, then rose by 1.43% to 0.39 in 2024, then increased by 8.71% to 0.43 in 2025.
  • Its Equity Ratio was 0.43 in Q4 2025, compared to 0.4 in Q3 2025 and 0.4 in Q2 2025.